单位：[a]Department of Hepatology, the First Hospital of Jilin University, Changchun, China[b]Department of Microbiology, Peking University Health Science Center, Beijing, China[c]Department of Hepatology, Fourth Hospital of Harbin Medical University, Harbin, China[d]Department of Hepatology, Baoding Infectious Disease Hospital, Baoding, China[e]Department of Hepatology, Henan Provincial People's Hospital, Zhengzhou, China[f]Department of Hepatology, Changzhou Third People's Hospital, Changzhou, China[g]Department of Hepatology, Hepatology Hospital of Jilin Province, Changchun, China[h]Department of Hepatology, The Second Xiangya Hospital of Central South University, Changsha, China[i]Department of Infectious Disease, Shenyang Sixth People's Hospital, Shenyang, China[j]Department of Infectious Disease, Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[k]Department of Infectious Disease, The First Affiliated Hospital of Nanchang University, Nanchang, China[l]Department of Hepatology, The Third People's Hospital of Zhenjiang, Zhenjiang, China[m]Department of Infectious Disease, China-Japan Friendship Hospital, Beijing, China[n]Department of Infectious Disease, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[o]Department of Hepatology, Beijing You’an Hoapital, Capital Medical University, Beijing, China[p]Department of Hepatology, the Second Hospital of Jilin University, Changchun, China[q]Department of Hepatology, the Second Hospital of Tianjin, Tianjing, China[r]Department of Hepatology, Peking University People's Hospital, Beijing, China
Background: In some previous studies, serum hepatitis B virus RNA (HBV RNA) was proposed as an HBV viral marker during therapy. However, the dynamic change of HBV RNA, the correlation of HBV RNA with cccDNA, and the combination of HBV RNA with known HBV markers in predicting entecavir (ETV) treatment outcome in the same cohort are rarely reported. Methods: A total of 111 HBeAg-positive patients were enrolled in our study. The dynamic changes of serum HBV RNA and the correlation of HBV RNA with other HBV markers were investigated in the early treatment period of 144-week ETV treatment. Intrahepatic cccDNA was detected at baseline and week 48. Receiver operating characteristic analyses were used to identify HBV RNA levels associated with HBeAg seroconversion. Results: The serum HBV RNA levels decreased more rapidly in patients with HBeAg seroconversion than those without HBeAg seroconversion. The levels of HBV RNA decreased slower compared with the serum HBV DNA, irrespective of whether the patients achieved HBeAg seroconversion or not. Although the serum HBV RNA was positively correlated with cccDNA at baseline among all patients, no significant correlation was observed in the patients with HBeAg seroconversion at week 48 (r = 0.094, P = 0.588). The area under the receiver operating characteristic (AUROC) of HBV RNA and HBeAg at week 24 was 0.754 and 0.800, respectively. The AUROC of the HBV RNA and HBeAg combination had a higher value (AUROC = 0.821). Conclusions: The level of HBV RNA at week 24 was a powerful predictor of HBeAg seroconversion in HBeAg-positive patients after 144-week ETV treatment, while the combination of HBV RNA and HBeAg was superior to HBV RNA alone in predicting HBeAg seroconversion. (c) 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
基金：
State Key Science & Technology Project for Infectious Diseases [2014ZX10002002, 2018ZX10732101]; Program for JLU Science and Technology Innovative Research Team [2017TD-08]
第一作者单位：[a]Department of Hepatology, the First Hospital of Jilin University, Changchun, China
共同第一作者：
通讯作者：
通讯机构：[a]Department of Hepatology, the First Hospital of Jilin University, Changchun, China[b]Department of Microbiology, Peking University Health Science Center, Beijing, China[*1]Department of Hepatology, the First Hospital of Jilin University, Changchun 130021, China.[*2]State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology & Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100083, China.
推荐引用方式(GB/T 7714)：
Xiaomei Wang,Zhongfeng Wang,Xiumei Chi,et al.Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks[J].INTERNATIONAL JOURNAL of INFECTIOUS DISEASES.2020,99:171-178.doi:10.1016/j.ijid.2020.07.031.
APA：
Xiaomei Wang,Zhongfeng Wang,Xiumei Chi,Ruihong Wu,Qinglong Jin...&Junqi Niu.(2020).Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks.INTERNATIONAL JOURNAL of INFECTIOUS DISEASES,99,
MLA：
Xiaomei Wang,et al."Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks".INTERNATIONAL JOURNAL of INFECTIOUS DISEASES 99.(2020):171-178
